News & Updates

Treatment with the oral highly selective JAK1 inhibitor ivarmacitinib appears to help reduce disease activity in patients with moderate-to-severe atopic dermatitis (AD), with up to 42 percent of them having complete or near-complete clearance of involved skin areas, according to the results of the pivotal phase III QUARTZ3 trial presented at AAD 2023.

Obesity appears to play a major role in the activation of the renin‒angiotensin‒aldosterone system (RAAS), with a noticeable rise of angiotensin-converting enzyme (ACE) and ACE activities during childhood, reveals a recent study. In addition, sex differences are present in the association of ACE and ACE2 activities with blood pressure (BP).

Intervene early. Cumulative exposure to common cardiovascular (CV) risk factors could be a harbinger of cardiovascular disease (CVD) in future.

Combination therapy with ceftolozane and tazobactam demonstrates a favourable safety profile in children with complicated urinary tract infection (cUTI) similar to that of meropenem and to the previously reported safety profile in adults with cUTI, a study has shown.

Children who are allergic to peanuts may benefit from two immunotherapies, one oral and another epicutaneous or on-the-skin, which have demonstrated safety and efficacy in separate studies presented at the recent AAAAI 2023.